IL-6 serves as a source of residual risk for atherosclerotic cardiovascular disease after standard risk factors
High levels of IL-6 signal risk for heart disease
This narrative review explores the role of IL-6 in atherosclerotic cardiovascular disease (ASCVD) and the effects of IL-6 inhibition. The re…
A specific protein called IL-6 may signal heart disease risk earlier than common tests, even in patients who have already had heart events.
IL-37 and IL-38 act as endogenous regulators of CAR-T-associated hyperinflammation in multiple myeloma
New Proteins May Help Control Inflammation in Multiple Myeloma Treatment
This mini-review explores the roles of IL-37 and IL-38 as potential immunoregulatory checkpoints in patients with relapsed/refractory multip…
Two specific proteins, IL-37 and IL-38, may help control dangerous inflammation during CAR-T cell therapy for multiple myeloma.
JAK and IL-6 inhibitors outperform TNF inhibitors for activity limitation in rheumatoid arthritis
Specific Biologic Drugs Show Better Results for Rheumatoid Arthritis
This meta-analysis of 99 studies evaluated patient-reported outcomes (PROs) in patients with rheumatoid arthritis treated with b/tsDMARDs. T…
New analysis shows that certain types of biologic drugs may better reduce activity limits and improve mental health for people with rheumato…
Biologic and targeted synthetic DMARDs show reassuring malignancy safety in inflammatory arthritides, but non-melanoma skin cancer risk rises with TNF inhibitors
Biologics for arthritis: Cancer risk appears low overall
This narrative review of biologic and targeted synthetic DMARDs in immune-mediated inflammatory arthritides finds most therapies have reassu…
Most biologic arthritis drugs don't raise overall cancer risk, but skin cancer risk may be higher with some.